Danish Study: 49% Stop Wegovy Within a Year, One in Four Restart
Health

Danish Study: 49% Stop Wegovy Within a Year, One in Four Restart

A nationwide Danish cohort finds high first-year semaglutide discontinuation, driven partly by cost and side effects, wi...

Noa Feldman 👁 32 💬 0
Eli Lilly's Foundayo Launch Puts UK Brokers on Counterfeit and Disclosure Watch
Insurance

Eli Lilly's Foundayo Launch Puts UK Brokers on Counterfeit and Disclosure Watch

The UK debut of Eli Lilly's daily Foundayo pill could widen non-disclosure in life, travel and private medical insurance...

Tamar Rosen 👁 39 💬 0
Eli Lilly's Foundayo Launch Puts UK Brokers on Counterfeit and Disclosure Watch
Insurance

Eli Lilly's Foundayo Launch Puts UK Brokers on Counterfeit and Disclosure Watch

The UK debut of Eli Lilly's daily Foundayo pill could widen non-disclosure in life, travel and private medical insurance...

Tamar Rosen 👁 40 💬 0
GLP-1 Drugs Are Moving Far Beyond Weight Loss — and Rewriting Chronic Disease Treatment
Health

GLP-1 Drugs Are Moving Far Beyond Weight Loss — and Rewriting Chronic Disease Treatment

New trial data link semaglutide and tirzepatide to improvements in sleep apnea, kidney, liver and heart outcomes, recast...

Noa Feldman 👁 46 💬 0
Why Splitting a GLP-1 Pill to Microdose Is Unsafe
Health

Why Splitting a GLP-1 Pill to Microdose Is Unsafe

Cutting oral GLP-1 tablets destroys the SNAC delivery system that protects the drug in the stomach, leading to inconsist...

Noa Feldman 👁 33 💬 0
A Patient's Guide to GLP-1 Side Effects: From GI Upset to Rare Eye Risks
Health

A Patient's Guide to GLP-1 Side Effects: From GI Upset to Rare Eye Risks

GLP-1 drugs are widely prescribed, but patients should understand the range of reported side effects — from common nause...

Noa Feldman 👁 42 💬 0
Bank of America Spends $250 Million a Year on Weight-Loss Drugs for Employees, CEO Says
Health

Bank of America Spends $250 Million a Year on Weight-Loss Drugs for Employees, CEO Says

The disclosure from CEO Brian Moynihan underscores how GLP-1 medications are reshaping corporate healthcare budgets and ...

Noa Feldman 👁 29 💬 0
Diabetes Market Surges Past $966 Billion as Patient Count Tops 537 Million
Health

Diabetes Market Surges Past $966 Billion as Patient Count Tops 537 Million

Global diabetes spending reached nearly $966 billion in 2021, driven by a disease burden affecting 10% of the world's po...

Noa Feldman 👁 37 💬 0
Eli Lilly's GLP-1 Juggernaut Powers 48% Revenue Jump, Eyes Next Obesity Blockbuster
Companies

Eli Lilly's GLP-1 Juggernaut Powers 48% Revenue Jump, Eyes Next Obesity Blockbuster

Quarterly sales topped $23 billion as Mounjaro and Zepbound dominate the obesity drug market. With a new oral pill and a...

Declan Byrne 👁 35 💬 0
ADA Review, Retatrutide Access and GLP-1 Generics Lead a Busy Diabetes Week
Health

ADA Review, Retatrutide Access and GLP-1 Generics Lead a Busy Diabetes Week

A busy week for diabetes and obesity drugs: ADA reviews a police incident, Lilly expands retatrutide access, Novo faces ...

Noa Feldman 👁 42 💬 0
Harris Teeter Now Delivers Prescriptions With Instacart Grocery Orders
Retail

Harris Teeter Now Delivers Prescriptions With Instacart Grocery Orders

Harris Teeter will deliver eligible prescriptions alongside Instacart grocery orders — its second pharmacy expansion in ...

Orla Fitzpatrick 👁 32 💬 0
Novo Nordisk Sheds $30 Billion as Heart Drug Trial Fails, Derailing Diversification Hopes
Companies

Novo Nordisk Sheds $30 Billion as Heart Drug Trial Fails, Derailing Diversification Hopes

A late-stage trial of Novo Nordisk's cardiovascular drug ziltivekimab failed to meet its primary goal, wiping out a pote...

Declan Byrne 👁 31 💬 0
Aging Is a Controllable Biological System — Here’s How Science Says You Can Stabilize It
Health

Aging Is a Controllable Biological System — Here’s How Science Says You Can Stabilize It

Research now frames aging as a dynamic system driven by metabolism, chronic inflammation, and epigenetic regulation. Thi...

Noa Feldman 👁 36 💬 0
The GLP-1 Paradox: MassHealth Cuts Coverage as Obesity Drugs Strain Budgets
Health

The GLP-1 Paradox: MassHealth Cuts Coverage as Obesity Drugs Strain Budgets

MassHealth will stop covering GLP-1 obesity medications, saving $15M a year but affecting 22,000 residents – a microcosm...

Noa Feldman 👁 47 💬 0